FATE
Fate Therapeutics Inc

6,298
Mkt Cap
$121.12M
Volume
1.21M
52W High
$3.43
52W Low
$0.661
PE Ratio
-0.80
FATE Fundamentals
Price
$1.00
Prev Close
$1.05
Open
$1.06
50D MA
$1.23
Beta
1.11
Avg. Volume
2.91M
EPS (Annual)
-$1.64
P/B
0.52
Rev/Employee
$75,309.39
Loading...
Loading...
News
all
press releases
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Average Rating of "Hold" by Brokerages
Shares of Fate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report) have been assigned a consensus rating of "Hold" from the nine brokerages that are presently covering the firm, Marketbeat.com...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
Fate Therapeutics (NASDAQ:FATE) Announces Quarterly Earnings Results
Fate Therapeutics (NASDAQ:FATE - Get Free Report) posted its earnings results on Thursday. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, topping analysts...
MarketBeat·6d ago
News Placeholder
Fate Therapeutics (FATE) Reports Q3 Loss, Beats Revenue Estimates
Fate Therapeutics (FATE) delivered earnings and revenue surprises of +6.90% and +104.82%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·7d ago
News Placeholder
Fate Therapeutics (FATE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Fate Therapeutics (FATE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·16d ago
News Placeholder
3 Cancer-Focused Stocks Showing Strong Pipeline Progress
Relay, Fate and Verastem advance promising cancer therapies, strengthening their pipelines in a rapidly evolving oncology market.
Zacks·23d ago
News Placeholder
Incyte (INCY) Tops Q3 Earnings and Revenue Estimates
Incyte (INCY) delivered earnings and revenue surprises of +36.14% and +8.71%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·23d ago
News Placeholder
Fate Therapeutics (FATE) Reports Q2 Loss, Beats Revenue Estimates
Fate Therapeutics (FATE) delivered earnings and revenue surprises of +17.14% and +190.70%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Tops Revenue Estimates
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of +32.00% and +21.29%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Health Catalyst (HCAT) Q2 Earnings and Revenues Beat Estimates
Health Catalyst (HCAT) delivered earnings and revenue surprises of +33.33% and +0.24%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago
News Placeholder
Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Misses Revenue Estimates
Viridian Therapeutics (VRDN) delivered earnings and revenue surprises of 0.00% and -48.63%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago

Latest FATE News

View

Advertisement|Remove ads.

Advertisement|Remove ads.